The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Exploring tarlatamab in the DeLLphi-301 trial for small cell lung cancer
Anna Minchom, MD, BCh, MB, MRCP, from The Royal Marsden Hospital, London, UK, discusses the investigation of tarlatamab in the DeLLphi-301 trial (NCT05060016). This Phase II trial explored two different doses (100 mg and 10 mg) and examined patient management strategies related to cytokine release syndrome (CRS). The results showed promising efficacy in terms of response rate and overall survival for patients with small cell lung cancer, despite the non-randomized nature of the study. Additionally, other DLL3-targeting T-cell engagers and tri-specific antibodies are emerging in early-stage development, highlighting the rapid progress in this field. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
